Aquestive Therapeutics (AQST) Stock Price, Quote, News & History | Benzinga

Aquestive Therapeutics Inc (AQST) Stock Price, Quote, News & History

AQSTNASDAQ

Trade with Public

Trade with Public

$5.28

-0.1-1.86%

Last update: Sep 3, 10:56 AM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$5.40

Close

-

Volume / Avg.

439.53K / 2.63M

Day Range

$5.26 - $5.44

52 Wk Range

2.93 - 7.55

Market Cap

$662.70M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

67

Short Interest

17.47%

Days to Cover

5.19

Recent Aquestive Therapeutics, Inc. News

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics reports positive study results for Anaphylm sublingual film, paving the way for a Q3 FDA resubmission.

Vandana Singh

Varex Imaging Posts Upbeat Q3 Earnings, Joins Bowman Consulting, MarineMax And Other Big Stocks Moving Higher On Monday

BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained 16.4%, AQST gained 15.4%, STDN rose 13.7%.

Avi Kapoor

Staar Surgical Posts Upbeat Q1 Results, Joins Cisco, Yeti Holdings And Other Big Stocks Moving Higher On Thursday

U.S. stocks rose, with Dow Jones up 300 points. STAA shares surged after better-than-expected results. Other big gainers include POET, STUB, MSC, ARX, CSCO, PCT, WOLF, CPA, ONDS, KLAR, and RDW.

Avi Kapoor

What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment?

Aquestive received an FDA rejection for its allergy film due to safety and use issues. The company plans new studies and targets resubmission in 2026.

Vandana Singh

Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-45.37M

Investing Cash Flow (TTM)

-584.00K

Financing Cash Flow (TTM)

83.90M

Free Cash Flow (TTM)

-45.95M

Capital Expenditure (TTM)

-584.00K

Net Change in Cash (TTM)

37.95M

Analyst Trends and Forecast

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.5

Strong Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$635.79M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

11.95

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-12.27%

Earnings Yield % (FWD)

-9.48%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$0.45

Company Debt

Total Debt

$50.69M

LT Debt

$50.65M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$48.92M

Total Cash

$98.49M

Debt to Equity

-

Issuance of Debt (TTM)

$5.42M

Repayment of Debt (TTM)

-$48.92M

Key Statistics

Open

$5.40

Close

-

Volume / Avg.

439.53K / 2.63M

Day Range

$5.26 - $5.44

52 Wk Range

2.93 - 7.55

Market Cap

$662.70M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

67

Short Interest

17.47%

Days to Cover

5.19

About

Sector

Health Care

Industry

Pharmaceuticals

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous Sys...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Aquestive Therapeutics (AQST) stock?

A

You can purchase shares of Aquestive Therapeutics (NASDAQ:AQST) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Aquestive Therapeutics (AQST) competitors?

A

Other companies in Aquestive Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Aquestive Therapeutics (AQST) stock?

A

Aquestive Therapeutics has a consensus price target of $9.90.

Q

What is the current price for Aquestive Therapeutics (AQST)?

A

The stock price for Aquestive Therapeutics (NASDAQ: AQST) is $5.28 last updated September 3, 2026 at 10:56 AM EDT.

Q

Does Aquestive Therapeutics (AQST) pay a dividend?

A

There are no upcoming dividends for Aquestive Therapeutics.

Q

When is Aquestive Therapeutics (NASDAQ:AQST) reporting earnings?

A

Aquestive Therapeutics does not have any upcoming earnings scheduled.

Q

Is Aquestive Therapeutics (AQST) going to split?

A

There is no upcoming split for Aquestive Therapeutics.

Q

What sector and industry does Aquestive Therapeutics (AQST) operate in?

A

Aquestive Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.